141 related articles for article (PubMed ID: 34232984)
1. Analytical Accuracy of RET Fusion Detection by Break-Apart Fluorescence In Situ Hybridization.
Baker JA; Sireci AN; Marella N; Cannon HK; Marquart TJ; Holzer TR; Reising LO; Cook JD; Wijayawardana SR; Bodo J; Hsi ED; Schade AE; Oakley GJ
Arch Pathol Lab Med; 2022 Mar; 146(3):351-359. PubMed ID: 34232984
[TBL] [Abstract][Full Text] [Related]
2. Pitfalls in RET Fusion Detection Using Break-Apart FISH Probes in Papillary Thyroid Carcinoma.
Liu Y; Wu S; Zhou L; Guo Y; Zeng X
J Clin Endocrinol Metab; 2021 Mar; 106(4):1129-1138. PubMed ID: 33382428
[TBL] [Abstract][Full Text] [Related]
3. An evaluation and recommendation of the optimal methodologies to detect RET gene rearrangements in papillary thyroid carcinoma.
Zhang T; Lu Y; Ye Q; Zhang M; Zheng L; Yin X; Gavine P; Sun Z; Ji Q; Zhu G; Su X
Genes Chromosomes Cancer; 2015 Mar; 54(3):168-76. PubMed ID: 25407564
[TBL] [Abstract][Full Text] [Related]
4. RET Fluorescence In Situ Hybridization Analysis Is a Sensitive but Highly Unspecific Screening Method for RET Fusions in Lung Cancer.
Radonic T; Geurts-Giele WRR; Samsom KG; Roemen GMJM; von der Thüsen JH; Thunnissen E; Meijssen IC; Sleddens HFBM; Dinjens WNM; Boelens MC; Weijers K; Speel EJM; Finn SP; O'Brien C; van Wezel T; Cohen D; Monkhorst K; Roepman P; Dubbink HJ
J Thorac Oncol; 2021 May; 16(5):798-806. PubMed ID: 33588111
[TBL] [Abstract][Full Text] [Related]
5. A Performance Comparison of Commonly Used Assays to Detect RET Fusions.
Yang SR; Aypar U; Rosen EY; Mata DA; Benayed R; Mullaney K; Jayakumaran G; Zhang Y; Frosina D; Drilon A; Ladanyi M; Jungbluth AA; Rekhtman N; Hechtman JF
Clin Cancer Res; 2021 Mar; 27(5):1316-1328. PubMed ID: 33272981
[TBL] [Abstract][Full Text] [Related]
6. Break-apart interphase fluorescence in situ hybridization assay in papillary thyroid carcinoma: on the road to optimizing the cut-off level for RET/PTC rearrangements.
Colato C; Vicentini C; Cantara S; Pedron S; Brazzarola P; Marchetti I; Di Coscio G; Chilosi M; Brunelli M; Pacini F; Ferdeghini M
Eur J Endocrinol; 2015 May; 172(5):571-82. PubMed ID: 25698220
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic method for the detection of KIF5B-RET transformation in lung adenocarcinoma.
Go H; Jung YJ; Kang HW; Park IK; Kang CH; Lee JW; Ju YS; Seo JS; Chung DH; Kim YT
Lung Cancer; 2013 Oct; 82(1):44-50. PubMed ID: 23932363
[TBL] [Abstract][Full Text] [Related]
8. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
[TBL] [Abstract][Full Text] [Related]
9. Optimizing detection of RET and PPARg rearrangements in thyroid neoplastic cells using a home-brew tetracolor probe.
Caria P; Frau DV; Dettori T; Boi F; Lai ML; Mariotti S; Vanni R
Cancer Cytopathol; 2014 May; 122(5):377-85. PubMed ID: 24510380
[TBL] [Abstract][Full Text] [Related]
10. Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
Lim SM; Chang H; Cha YJ; Liang S; Tai YC; Li G; Pestova E; Policht F; Perez T; Soo RA; Park WY; Kim HR; Shim HS; Cho BC
Lung Cancer; 2017 Sep; 111():79-83. PubMed ID: 28838404
[TBL] [Abstract][Full Text] [Related]
11. A break-apart fluorescence in situ hybridization assay for detecting RET translocations in papillary thyroid carcinoma.
Chen F; Clark DP; Hawkins AL; Morsberger LA; Griffin CA
Cancer Genet Cytogenet; 2007 Oct; 178(2):128-34. PubMed ID: 17954268
[TBL] [Abstract][Full Text] [Related]
12. Expert consensus on the diagnosis and treatment of RET gene fusion non-small cell lung cancer in China.
Pu X; Xu C; Wang Q; Wang W; Wu F; Cai X; Song Z; Yu J; Zhong W; Wang Z; Zhang Y; Liu J; Zhang S; Liu A; Li W; Zhan P; Liu H; Lv T; Miao L; Min L; Lin G; Huang L; Yuan J; Jiang Z; Rao C; Lv D; Yu Z; Li X; Tang C; Zhou C; Zhang J; Guo H; Chu Q; Meng R; Liu X; Wu J; Zhou J; Zhu Z; Pan W; Pang F; Huang J; Wang K; Wu F; Shen T; Zou S; Xu B; Wang L; Zhu Y; Lin X; Cai J; Xu L; Li J; Jiao X; Li K; Feng H; Wang L; Du Y; Yao W; Shi X; Niu X; Yuan D; Yao Y; Kang J; Zhang J; Zhang C; Fu J; Huang J; Zhang Y; Sun P; Wang H; Ye M; Wang D; Wang Z; Hao Y; Wang Z; Wan B; Lv D; Lan G; Yang S; Shi L; Wang Y; Li B; Zhang Z; Li Z; Li Y; Liu Z; Yang N; Wang H; Huang W; Hong Z; Wang G; Wang J; Fang M; Fang Y; Zhu X; Shen Y; Zhang Y; Ma S; Song Y; Lu Y; Fang W; Li Z; Wu L
Thorac Cancer; 2023 Nov; 14(31):3166-3177. PubMed ID: 37718634
[TBL] [Abstract][Full Text] [Related]
13. Assessing RET/PTC in thyroid nodule fine-needle aspirates: the FISH point of view.
Caria P; Dettori T; Frau DV; Borghero A; Cappai A; Riola A; Lai ML; Boi F; Calò P; Nicolosi A; Mariotti S; Vanni R
Endocr Relat Cancer; 2013 Aug; 20(4):527-36. PubMed ID: 23722226
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R
Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569
[TBL] [Abstract][Full Text] [Related]
15. Detection of RET rearrangements in papillary thyroid carcinoma using RT-PCR and FISH techniques - A molecular and clinical analysis.
Musholt TJ; Staubitz JI; Antonio Cámara RJ; Musholt PB; Humberg D; Springer E; Schad A
Eur J Surg Oncol; 2019 Jun; 45(6):1018-1024. PubMed ID: 30472213
[TBL] [Abstract][Full Text] [Related]
16. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ
Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552
[TBL] [Abstract][Full Text] [Related]
17. Identification of
Reguart N; Teixidó C; Giménez-Capitán A; Paré L; Galván P; Viteri S; Rodríguez S; Peg V; Aldeguer E; Viñolas N; Remon J; Karachaliou N; Conde E; Lopez-Rios F; Nadal E; Merkelbach-Bruse S; Büttner R; Rosell R; Molina-Vila MA; Prat A
Clin Chem; 2017 Mar; 63(3):751-760. PubMed ID: 28073897
[TBL] [Abstract][Full Text] [Related]
18. Novel targets in non-small cell lung cancer: ROS1 and RET fusions.
Gainor JF; Shaw AT
Oncologist; 2013; 18(7):865-75. PubMed ID: 23814043
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients.
Song Z; Yu X; Zhang Y
Cancer Biol Ther; 2017 Nov; 18(11):883-887. PubMed ID: 27635639
[TBL] [Abstract][Full Text] [Related]
20. Predictive molecular pathology in metastatic thyroid cancer: the role of
Nacchio M; Pisapia P; Pepe F; Russo G; Vigliar E; Porcelli T; Luongo C; Iaccarino A; Pagni F; Salvatore D; Troncone G; Malapelle U; Bellevicine C
Expert Rev Endocrinol Metab; 2022 Mar; 17(2):167-178. PubMed ID: 35404189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
